[ Search ] [ Legislation ] [ Bill Summary ]
[ Home ] [ Back ] [ Bottom ]
| [ Introduced ] | [ Senate Amendment 001 ] |
90_SJ0035eng 90SJ0035 Engrossed LRB9005666JSgcB 1 SENATE JOINT RESOLUTION 35 2 (As amended by Senate Amendment No. 1) 3 WHEREAS, The General Assembly recognizes that cancer 4 clinical trials are designed to compare the effectiveness of 5 the standard medical treatment with a new therapy that 6 researchers believe will prove more effective, based on 7 scientific evidence and that such research provides the 8 foundation for improved patient care and decreased health 9 care costs; and 10 WHEREAS, The General Assembly recognizes that cancer 11 clinical trials involve a rigorously developed clinical 12 protocol that includes goals, rationale and background, 13 criteria for patient selection, specific directions for 14 administering therapy and monitoring patients, definition of 15 quantitative measures for determining treatment response, and 16 methods for documenting and treating adverse reactions; and 17 WHEREAS, The General Assembly recognizes that virtually 18 every major breakthrough for current standard medical 19 treatment has been developed through the clinical trial 20 system; and 21 WHEREAS, It is the intent of the General Assembly to 22 determine how the costs associated with cancer clinical 23 trials compare with the costs of standard therapy; therefore, 24 be it 25 RESOLVED, BY THE SENATE OF THE NINETIETH GENERAL ASSEMBLY 26 OF THE STATE OF ILLINOIS, THE HOUSE OF REPRESENTATIVES 27 CONCURRING HEREIN, that a Cancer Clinical Trials Task Force 28 is created; and be it further 29 RESOLVED, That with the assistance of a scientifically 30 recognized research facility, the Cancer Clinical Trials Task 31 Force shall review the claims and billing data from a sample 32 of the most current data available for Phase I, II, III, and 90SJ0035 Engrossed -2- LRB9005666JSgcB 1 IV cancer trial and non-trial patients, including a sample of 2 patients having lung, breast, prostate, colon, and ovarian 3 cancer; and be it further 4 RESOLVED, That patient privacy and confidentiality of 5 medical records shall be maintained; and be it further 6 RESOLVED, That the Cancer Clinical Trials Task Force 7 shall submit a report identifying and explaining any 8 incremental cost to the insurance industry that results from 9 cancer patients' participation in valid cancer clinical 10 trials to the Governor and General Assembly not later than 11 January 1, 1999; and be it further 12 RESOLVED, That on or before October 1, 1997, the 13 President of the Senate shall appoint 2 members of the Senate 14 to the Task Force, designating one member as co-chairperson, 15 the Minority Leader of the Senate shall appoint one member of 16 the Senate to the Task Force, the Speaker of the House of 17 Representatives shall appoint 2 members of the House to the 18 Task Force, designating one member as co-chairperson, and the 19 Minority Leader of the House of Representatives shall appoint 20 one member of the House to the Task Force; the Director of 21 Public Health, the Director of Insurance, and the Director of 22 Central Management or their respective designees shall serve 23 as ex-officio members of the Task Force; and the remainder of 24 the Task Force shall consist of 4 members of the public 25 appointed by the President of the Senate, 2 members of the 26 public appointed by the Minority Leader of the Senate, 4 27 members of the public appointed by the Speaker of the House 28 of Representatives, and 2 members of the public appointed by 29 the Minority Leader of the House of Representatives; and be 30 it further 31 RESOLVED, That the members of the Cancer Clinical Trials 32 Task Force shall serve without compensation, but may be 90SJ0035 Engrossed -3- LRB9005666JSgcB 1 reimbursed for their necessary expenses; and be it further 2 RESOLVED, That a copy of this resolution shall be 3 transmitted to the Directors of Public Health, Insurance, and 4 Central Management Services.